Showing 1591-1600 of 5603 results for "".
CDC - TB & HIV: A Deadly Duo, Part 3
https://reachmd.com/programs/grand-rounds-nation/cdc-tb-hiv-a-deadly-duo-part-3/6392/The CDC commemorates Dr. Robert Koch's 1882 discovery of Mycobacterium tuberculosis, the bacteria that causes TB. Over the past 129 years, history has witnessed many advances over in TB control. Through the intervention efforts of CDC, USAID, WHO's Stop TB Partnership, and many others, TB deathCDC - TB & HIV: A Deadly Duo, Part 2
https://reachmd.com/programs/grand-rounds-nation/cdc-tb-hiv-a-deadly-duo-part-2/6391/The CDC commemorates Dr. Robert Koch's 1882 discovery of Mycobacterium tuberculosis, the bacteria that causes TB. Over the past 129 years, history has witnessed many advances over in TB control. Through the intervention efforts of CDC, USAID, WHO's Stop TB Partnership, and many others, TB deathFrom Pixels to Practice: Advancing HCM Care With Multimodality Imaging
https://reachmd.com/programs/cme/from-pixels-to-practice-advancing-hcm-care-with-multimodality-imaging/39877/Explore how multimodality imaging advances diagnosis, treatment selection, and monitoring in hypertrophic cardiomyopathy care.Catching Demodex in the Act
https://reachmd.com/programs/cme/Catching-Demodex-in-the-Act/56703/Join Drs. Devries and Koetting evaluate screening methods for accurate diagnosis of Demodex blepharitis and optimal treatment strategies for this condition.Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
https://reachmd.com/programs/cme/optimizing-outcomes-in-patients-with-ohcm-the-emerging-role-of-cardiac-myosin-inhibitors/33176/Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin InhibitorsThe Neverending Journey: A 66-Year-Old Patient Who Has Undergone Several Rounds of Tea Tree Oil–Based Treatment
https://reachmd.com/programs/cme/the-neverending-journey-a-66-year-old-patient-who-has-undergone-several-rounds-of-tea-tree-oilbased-treatment/56707/Join Drs. Devries and Koetting evaluate screening methods for accurate diagnosis of Demodex blepharitis and optimal treatment strategies for this condition.Return and Revisit: A 38-Year-Old Patient Returns for Follow-up After Lotilaner Treatment
https://reachmd.com/programs/cme/return-and-revisit-a-38-year-old-patient-returns-for-follow-up-after-lotilaner-treatment/56709/Join Drs. Devries and Koetting evaluate screening methods for accurate diagnosis of Demodex blepharitis and optimal treatment strategies for this condition.Key Takeaways and Practice Integration
https://reachmd.com/programs/cme/Key-Takeaways-and-Practice-Integration/56710/Join Drs. Devries and Koetting evaluate screening methods for accurate diagnosis of Demodex blepharitis and optimal treatment strategies for this condition.Closing the Loop: Structured Follow-Up and Patient Communication
https://reachmd.com/programs/cme/closing-the-loop-structured-follow-up-and-patient-communication/56708/Join Drs. Devries and Koetting evaluate screening methods for accurate diagnosis of Demodex blepharitis and optimal treatment strategies for this condition.Inside the 4 Hits: Targeting APRIL to Change the Course of IgAN
https://reachmd.com/programs/cme/inside-the-4-hits-targeting-april-to-change-the-course-of-igan/48815/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.